Your last forty years don't have to be your worst.
Four diseases drive the majority of decline. We use advanced biomarker and genomic testing to find them early — then build the protocol that keeps you functional for decades, not just alive.
Led by Lily Woods, PhD — precision genomics.
Most medicine manages disease. We work to keep it from starting.
Test deeper than standard care
Advanced panels and genomics reveal risk years before a routine physical would — while there's still time to change the trajectory.
A protocol built around you
Your results, your biology, your goals. The testing drives every decision — no generic templates, no guesswork.
We stay the Watchman
We measure, we correct where things drift, and we keep watch. Longevity is a practice, not a one-time report.
The average American life is 4,000 weeks.
Roughly 77 years — and since 2013, U.S. life expectancy has been falling. We're not just running out of time; we're spending more of it in poor health.
Today's centenarians didn't biohack their way there — most won a genetic lottery with odds near 1 in 5,000. The goal here is different, and it's within reach: stay at full function for as long as possible, then decline quickly only at the very end. That means preventing or delaying the diseases that would otherwise arrive in your 50s and 60s, and pushing them into your 80s, 90s, or out of your life entirely.
Four categories account for over 80% of deaths among non-smokers.
They're largely addressable with the right interventions — but only if you can see them coming. Here's how we go deep on each one.
ASCVD
Cardiovascular disease and stroke — still America's leading killer by a wide margin, and a driver of vascular dementia.
- ApoB and Lp(a) — the lipid markers standard panels miss
- Coronary artery calcium (CAC) scoring
- Advanced lipid subfractions and hs-CRP inflammation
- Blood pressure, glycemic and lifestyle risk mapping
Cancer
The earlier it's found, the more options you have. We layer molecular screening with your inherited risk profile.
- Multi-cancer early detection (MCED) blood screening
- Hereditary and genomic risk assessment
- Targeted imaging when results warrant it
- Metabolic and inflammatory terrain markers
Neurodegenerative Disease
What protects the heart protects the brain. We baseline cognition early and track the vascular and metabolic drivers behind it.
- Cognitive baselining and longitudinal tracking
- APOE genotyping and genomic risk
- Neuro-inflammatory and metabolic markers
- Vascular risk shared with the ASCVD workup
Metabolic Dysfunction
Diabetes, fatty liver, and insulin resistance start silently — and quietly fuel the other three horsemen.
- Fasting insulin and HbA1c
- Continuous glucose monitoring (CGM)
- Liver and visceral fat assessment
- Full lipid and inflammatory context
We don't know your six pathways until we run your report.
That's the point. The Six Pathway System doesn't sort you into a category that already exists — it derives the six pathways driving your biology, from your labs, your genetics, and your full intake, through deep research run on your case specifically.
Nobody else gets your six. What comes back isn't a handout with your name on top; it's a program designed around what your own results turned out to say, with the reasoning shown so you understand every recommendation in it.
Your data goes in
Labs, genetics, and a full intake — the complete picture, not a snapshot.
Deep research runs on your case
Your results are worked against the current evidence, specific to you.
Your six pathways emerge
The research reveals which pathways are actually driving your risk. They're an output, not a menu.
Your protocol is designed
A customized program built on those six, with the reasoning behind every recommendation.
How we crush through the 4,000 weeks.
Plan with purpose
Together we outline a path that's realistic, strategic, and tailored to your situation. We choose the right tests, then go deep.
Collaborate openly
You're part of the process. Communication stays open and decisions are shared — no black boxes, no surprises.
Design the protocol
Now we know the targets, and we know you. We design exactly what to do next and precisely how we'll measure progress.
Remeasure and adapt
As you progress, we keep watch — adjusting the protocol so the gains hold and the trajectory stays vital.
The first step is a single conversation.
Book a longevity assessment. We'll review where you stand today, map which of the four horsemen matter most for you, and lay out exactly what testing comes next.
You'll leave with a clear picture of your baseline — and a plan for the years that matter most.